Literature DB >> 2114983

Accelerated atherogenesis occurs following platelet destruction and increases in megakaryocyte size and DNA content.

S D Kristensen1, K M Roberts, Y T Kishk, J F Martin.   

Abstract

Platelets and megakaryocytes have a role in atherogenesis. In this study the effect of platelet destruction, caused by injection of serum containing anti-platelet antibodies, on the development of atheroma and on megakaryocyte size and DNA content was studied in rabbits on a high cholesterol diet. Seven days after destruction of the circulating platelets a significant (150% and 300% in two separate studies) increase in the area of atheroma in the aorta was demonstrated. Histological examination revealed that large quantities of extracellular lipid and connective tissue were present in these plaques. The acceleration of atherogenesis in this model was found to be preceded by a significant increase in megakaryocyte size and in the frequency of megakaryocytes with a high DNA content. Platelets derived from large, high ploidy megakaryocytes may be of importance for the development of the atherosclerotic lesion. Neither the endothelial permeability as assessed by injection of Evans blue nor the prostacyclin production by the aorta of animals injected with anti-platelet serum were significantly different from the aortas of control animals.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2114983     DOI: 10.1111/j.1365-2362.1990.tb01850.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  2 in total

1.  Thrombopoietin and mean platelet volume in coronary artery disease.

Authors:  H Senaran; M Ileri; A Altinbaş; A Koşar; E Yetkin; M Oztürk; Y Karaaslan; S Kirazli
Journal:  Clin Cardiol       Date:  2001-05       Impact factor: 2.882

Review 2.  The causal role of megakaryocyte–platelet hyperactivity in acute coronary syndromes.

Authors:  John F Martin; Steen D Kristensen; Anthony Mathur; Erik L Grove; Fizzah A Choudry
Journal:  Nat Rev Cardiol       Date:  2012-11       Impact factor: 32.419

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.